Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease

BMC Neuroscience

Table 1 Clinical characteristics of Parkinson’s disease patients

	PD patients
No (M, %)	41 (24, 58.5%)
Age (years; median ± SD)	65.0 ± 9.3
Disease duration^a (months; median ± SD)	84.0 ± 71.8
Daily LED (mg; median ± SD)	480.0 ± 957.7
H&Y (median ± SD)	2.0 ± 1.0
NMSS (median ± SD)	37.0 ± 31.4
NMSS Domain 2: sleep/fatigue (median ± SD)	4.0 ± 7.7
NMS Domain 6: gastrointestinal tract (median ± SD)	3.0 ± 6.0
NMSQ (median ± SD)	8.0 ± 5.9
MMSE (median ± SD)	30.0 ± 1.3
PDQ-39 [(median ± SD) ± SD]	27.5 ± 24.4

H&Y Hoein & Yahr, LED levodopa equivalent dose, MMSE mini mental status examination, NMSS Non-motor Symptoms Scale, NMSQ Non-motor Symptoms Questionnaire, PDQ-39 39-item Parkinson’s disease Questionnaire
^aFrom time of first appearance of Parkinson’s disease motor symptoms

ISSN: 1471-2202